Remix Therapeutics
@remixtx.bsky.social
Clinical-stage #biotech company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin.
Our CSO, Dom Reynolds, PhD, will be highlighting the development of REM-422 for ACC, AML, and high-risk MDS and how our REMaster™ platform is advancing RNA-targeted drug discovery at the 8th RNA-Targeted Drug Discovery & Development Summit. #REM422 #mRNA #RemixTherapeutics
November 19, 2025 at 6:26 PM
Our CSO, Dom Reynolds, PhD, will be highlighting the development of REM-422 for ACC, AML, and high-risk MDS and how our REMaster™ platform is advancing RNA-targeted drug discovery at the 8th RNA-Targeted Drug Discovery & Development Summit. #REM422 #mRNA #RemixTherapeutics
Our CEO, Pete Smith, PhD, will be attending the London Growth Summit, hosted by LifeSci Capital and
Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies
Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics
Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies
Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics
November 11, 2025 at 3:26 PM
Our CEO, Pete Smith, PhD, will be attending the London Growth Summit, hosted by LifeSci Capital and
Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies
Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics
Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies
Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics
Our Co-Founder and CEO, Pete Smith, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10 at 2:15 PM ET. The Remix management team will also be hosting one-on-one meetings with investors.
➡️https://bit.ly/4qEuRml
➡️https://bit.ly/4qEuRml
November 3, 2025 at 2:03 PM
Our Co-Founder and CEO, Pete Smith, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10 at 2:15 PM ET. The Remix management team will also be hosting one-on-one meetings with investors.
➡️https://bit.ly/4qEuRml
➡️https://bit.ly/4qEuRml
Our Co-Founder and CEO, Pete Smith, and Chief Business Officer, Heather Wasserman, will be participating in the Wells Fargo Virtual Private Biopharma Symposium on November 5.
If you would like to schedule a meeting, please reach out to: info@remixtx.com. #RemixTherapeutics
If you would like to schedule a meeting, please reach out to: info@remixtx.com. #RemixTherapeutics
October 30, 2025 at 3:42 PM
Our Co-Founder and CEO, Pete Smith, and Chief Business Officer, Heather Wasserman, will be participating in the Wells Fargo Virtual Private Biopharma Symposium on November 5.
If you would like to schedule a meeting, please reach out to: info@remixtx.com. #RemixTherapeutics
If you would like to schedule a meeting, please reach out to: info@remixtx.com. #RemixTherapeutics
Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8
bit.ly/4ozZes8
October 24, 2025 at 2:03 PM
Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8
bit.ly/4ozZes8
Next week at the 8th Annual TPD & Induced Proximity Summit in Boston, our Chief Scientific Officer, Dom Reynolds, PhD, will be chairing a panel on “Next Gen Novel Molecular Glue Discovery” and presenting on “Strategies to Drug RNA-Protein Complexes with Small Molecules.”
October 23, 2025 at 1:45 PM
Next week at the 8th Annual TPD & Induced Proximity Summit in Boston, our Chief Scientific Officer, Dom Reynolds, PhD, will be chairing a panel on “Next Gen Novel Molecular Glue Discovery” and presenting on “Strategies to Drug RNA-Protein Complexes with Small Molecules.”
Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
➡️ bit.ly/48u70iy
➡️ bit.ly/48u70iy
October 13, 2025 at 4:43 PM
Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
➡️ bit.ly/48u70iy
➡️ bit.ly/48u70iy
Join us next week for the @bloodcancerunited.bsky.social Light the Night Boston! We will be walking with thousands of others to honor those affected by blood cancers for greater awareness, research & support. #LightTheNight #LLS #RemixTherapeutics
Learn more: bit.ly/3VVRuo8
Learn more: bit.ly/3VVRuo8
October 9, 2025 at 12:54 PM
Join us next week for the @bloodcancerunited.bsky.social Light the Night Boston! We will be walking with thousands of others to honor those affected by blood cancers for greater awareness, research & support. #LightTheNight #LLS #RemixTherapeutics
Learn more: bit.ly/3VVRuo8
Learn more: bit.ly/3VVRuo8
Our CSO, Dom Reynolds, breaks down the science behind Remix’s pioneering new approach to treating difficult to drug diseases by targeting the cellular complexes that process RNA & working upstream of conventional therapeutic approaches.
➡️ More here: bit.ly/3VGrT2o
➡️ More here: bit.ly/3VGrT2o
September 29, 2025 at 3:44 PM
Our CSO, Dom Reynolds, breaks down the science behind Remix’s pioneering new approach to treating difficult to drug diseases by targeting the cellular complexes that process RNA & working upstream of conventional therapeutic approaches.
➡️ More here: bit.ly/3VGrT2o
➡️ More here: bit.ly/3VGrT2o
📣 Remix Chief Scientific Officer, Dominic Reynolds, PhD, will be speaking at the Small Molecules Targeting RNA & DNA Conference during the Discovery on Target event in Boston Sept 23-24. #RNAtherapeutics #RNAdegraders #RNAdegradation #mRNA #OncologyResearch
September 17, 2025 at 2:29 PM
📣 Remix Chief Scientific Officer, Dominic Reynolds, PhD, will be speaking at the Small Molecules Targeting RNA & DNA Conference during the Discovery on Target event in Boston Sept 23-24. #RNAtherapeutics #RNAdegraders #RNAdegradation #mRNA #OncologyResearch
Hear from Remix’s Maria Alexis, Principal Scientist, Computational Biology, about the team’s published work on poison exons & how deeper insights into RNA biology are shaping the future of medicine.
➡️http://bit.ly/4pcj0v5
➡️http://bit.ly/4pcj0v5
September 10, 2025 at 1:27 PM
Hear from Remix’s Maria Alexis, Principal Scientist, Computational Biology, about the team’s published work on poison exons & how deeper insights into RNA biology are shaping the future of medicine.
➡️http://bit.ly/4pcj0v5
➡️http://bit.ly/4pcj0v5
#BloodCancerAwarenessMonth is an important time to support patients and accelerate progress. Our lead program, REM-422, is in development for AML, which is one of the hardest-to-treat blood cancers with limited, effective treatment options.
September 3, 2025 at 3:04 PM
#BloodCancerAwarenessMonth is an important time to support patients and accelerate progress. Our lead program, REM-422, is in development for AML, which is one of the hardest-to-treat blood cancers with limited, effective treatment options.
Our team’s work to enable the discovery of small molecule modulators of mRNA processing to quantify transcript levels of multiple independent target genes within a single HTS campaign was published this week in ASSAY and Drug Development Technologies.
Read more: bit.ly/45QKz4a
Read more: bit.ly/45QKz4a
August 27, 2025 at 5:31 PM
Our team’s work to enable the discovery of small molecule modulators of mRNA processing to quantify transcript levels of multiple independent target genes within a single HTS campaign was published this week in ASSAY and Drug Development Technologies.
Read more: bit.ly/45QKz4a
Read more: bit.ly/45QKz4a
Today, we were honored to host cancer survivor and advocate Coney Flowers at Remix as we gear up for the #LightTheNight walk with The Leukemia & Lymphoma Society. Her story inspired hope and strengthened our commitment to new treatments for patients with blood disorders. Thank you, Coney!
August 19, 2025 at 3:42 PM
Today, we were honored to host cancer survivor and advocate Coney Flowers at Remix as we gear up for the #LightTheNight walk with The Leukemia & Lymphoma Society. Her story inspired hope and strengthened our commitment to new treatments for patients with blood disorders. Thank you, Coney!
Excellent discussion at the Canaccord Genuity 45th Annual Growth Conf, including our innovative REMaster discovery platform, the importance of targeting MYB as a driver of disease, the advancing clinical trials of REM-422 in ACC and AML, and our broader pipeline and partnerships.
August 13, 2025 at 1:11 PM
Excellent discussion at the Canaccord Genuity 45th Annual Growth Conf, including our innovative REMaster discovery platform, the importance of targeting MYB as a driver of disease, the advancing clinical trials of REM-422 in ACC and AML, and our broader pipeline and partnerships.
Remix CEO and Co-Founder, Pete Smith will be taking part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston next week. #RemixTherapeutics
August 5, 2025 at 2:05 PM
Remix CEO and Co-Founder, Pete Smith will be taking part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston next week. #RemixTherapeutics
MYB is an oncogenic transcription factor that is dysregulated in cancers like ACC, AML, and HR-MDS. Our lead program, REM-422, is an oral mRNA degrader that reduces MYB mRNA and protein expression, resulting in antitumor activity in MYB-dependent human tumor models.
➡️http://bit.ly/4kJkYQ4
➡️http://bit.ly/4kJkYQ4
July 21, 2025 at 1:09 PM
MYB is an oncogenic transcription factor that is dysregulated in cancers like ACC, AML, and HR-MDS. Our lead program, REM-422, is an oral mRNA degrader that reduces MYB mRNA and protein expression, resulting in antitumor activity in MYB-dependent human tumor models.
➡️http://bit.ly/4kJkYQ4
➡️http://bit.ly/4kJkYQ4
📣Next week, Co-Founder & CEO, Pete Smith, will be presenting on an Oncology panel and part of a Q&A session at Evercore's Emerging Private Biotech Conference. Looking forward to discussing Remix’s approach to tackling diseases by modulating RNA processing with small molecules. #Evercore #REM422
July 10, 2025 at 4:21 PM
🌈 Proud to welcome OUTbio Founder Ramsey Johnson for a powerful session on OUTbio’s mission to empower LGBTQ professionals and allies across the industry. At Remix, we’re committed to fostering a culture of inclusion, authenticity, and belonging—within our walls and across biotech. Thank you!
June 24, 2025 at 1:02 PM
🌈 Proud to welcome OUTbio Founder Ramsey Johnson for a powerful session on OUTbio’s mission to empower LGBTQ professionals and allies across the industry. At Remix, we’re committed to fostering a culture of inclusion, authenticity, and belonging—within our walls and across biotech. Thank you!
Data presented in poster sessions at the @theaacr.bsky.social and European Hematology Association Conferences demonstrate the importance of the MYB protein as the driver of diseases like ACC and AML.
Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D
Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D
June 17, 2025 at 3:02 PM
Data presented in poster sessions at the @theaacr.bsky.social and European Hematology Association Conferences demonstrate the importance of the MYB protein as the driver of diseases like ACC and AML.
Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D
Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D
See you at BIO International next week! Heather Wasserman, Remix's CBO/COO will be onsite and looking forward to meeting with current partners and networking with new colleagues about Remix's innovative approach to addressing the intractable drivers of disease. #OncologyResearch #BIO2025
June 14, 2025 at 3:32 PM
See you at BIO International next week! Heather Wasserman, Remix's CBO/COO will be onsite and looking forward to meeting with current partners and networking with new colleagues about Remix's innovative approach to addressing the intractable drivers of disease. #OncologyResearch #BIO2025
Sarah Sirin, Director & Head of Computational Chemistry, participated in Scientific Computing World’s roundtable on the data impact of working with emerging modalities, like RNA therapeutics and protein degraders.
Learn more: bit.ly/3ZmPmbg
Learn more: bit.ly/3ZmPmbg
June 9, 2025 at 1:15 PM
Sarah Sirin, Director & Head of Computational Chemistry, participated in Scientific Computing World’s roundtable on the data impact of working with emerging modalities, like RNA therapeutics and protein degraders.
Learn more: bit.ly/3ZmPmbg
Learn more: bit.ly/3ZmPmbg
Learn more about Remix’s innovative approach to drug design. Head of Medicinal Chemistry, Benoit Moreau, will be speaking at the 2nd Structure Based Drug Design Summit Meeting & the Precision in Drug Discovery & Preclinical Summit: bit.ly/42KveRd
bit.ly/3Y9k1YT
bit.ly/3Y9k1YT
June 2, 2025 at 4:14 PM
Learn more about Remix’s innovative approach to drug design. Head of Medicinal Chemistry, Benoit Moreau, will be speaking at the 2nd Structure Based Drug Design Summit Meeting & the Precision in Drug Discovery & Preclinical Summit: bit.ly/42KveRd
bit.ly/3Y9k1YT
bit.ly/3Y9k1YT
Closing out #mentalhealthmonth, we reflect on how we create a healthier, more human workplace at Remix - staying grounded and connected as a team by focusing on our mission while recharging with things like yoga, volunteering on the Charles, and showing up in green to support the cause.
May 28, 2025 at 3:23 PM
Closing out #mentalhealthmonth, we reflect on how we create a healthier, more human workplace at Remix - staying grounded and connected as a team by focusing on our mission while recharging with things like yoga, volunteering on the Charles, and showing up in green to support the cause.
This week, we hosted students from EVkids, a nonprofit that supports Boston youth, for a hands-on intro to biotech at Remix! From extracting a strawberry's DNA to learning how AI powers drug discovery, they explored the many career paths science has to offer. Grateful to be part of their journey!👨🔬🧬
May 22, 2025 at 1:14 PM
This week, we hosted students from EVkids, a nonprofit that supports Boston youth, for a hands-on intro to biotech at Remix! From extracting a strawberry's DNA to learning how AI powers drug discovery, they explored the many career paths science has to offer. Grateful to be part of their journey!👨🔬🧬